Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Variant Type

CCND1-IGH Fusion is present in 0.15% of AACR GENIE cases, with mantle cell lymphoma, multiple myeloma, endometrial endometrioid adenocarcinoma, follicular lymphoma, and mature B-cell neoplasm having the greatest prevalence [4].

Top Disease Cases with CCND1-IGH Fusion

Biomarker-Directed Therapies

Significance of CCND1-IGH Fusion in Diseases

Mantle Cell Lymphoma +

Mature B-Cell Lymphoma/Leukemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.